Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]Fluciclatide PET for Prediction of Response to Pazopanib in Metastatic RCC
NCT01961583Phase 2Terminated
- Sponsor
- Asan Medical Center
- Start
- Sep 2013
- Primary completion
- Apr 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluciclatide in renal cell carcinoma (RCC), sponsored by Asan Medical Center. Primary endpoint: Baseline 18F-Fluciclatide PET Standardized Uptake Value. Started Sep 2013; status: terminated.
02
Drugs
fluciclatide
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01961583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01961583.